Virtual Library
Start Your Search
M
Author of
-
+
IASLC Pre-Conference School of Nursing (ID 3)
- Event: LALCA 2019
- Type: Invited Speaker Session
- Track:
- Presentations: 1
- Moderators:
- Coordinates: 10/17/2019, 09:00 - 15:30, Castillo A 5-6
-
+
PC3.11 - Advances in Radiation Therapy (ID 36)
09:00 - 15:30 | Author(s): M
- Abstract
Radiotherapy treatments have evolved in the last two decades in an impressive way, from the 2D planning to the IMRT and SABR treatments, several intermediate modalities have been evolving and this has permitted that the oncologic treatments become saver and more efficient. In our Country also this technology has become more available and more people have access to this type of treatment and benefit from it. This is the reason why this is so important to describe each radiotherapy technique and its therapeutic implications and clinical uses. In this talk we also are going to present the result of a phase II study of SABR in oligometastatic lung cancer patients.
This talk is about the evolution of radiotherapy, the innovations and the characteristics of patients that are receiving this type of treatment. Also, the importance of speaking about these new approaches with the oncologic team in order to select the best option for every patient. We are going to present the results of a phase II study of SABR in oligometastatic lung cancer patients. Patients with stage IV non-small cell lung cancer, treated initially with systemic therapy and those with partial response, with thoracic residual disease, received treatment with SABR. The aim of the study is to report local control (LC), progression free survival (PFS) and overall survival (OS) after the SABR treatment.
Describe the results of the study, how local control to oligometastatic disease can benefit the patient in terms of progression free survival and overall survival and also the feasibility of this new technic of radiation therapy treatment and its high tolerability among patients. In Mexico this type of technology is becoming more available.
The evolution of radiation treatment has been impressive in the last two decades and now we can see that treatments are becoming more efficient and less toxic due to the high doses delivered to tumor cells in contrast to low doses to organs at risk.
